Yield10 Bioscience Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Yield10 Bioscience, Inc. (YTEN) Reports Q2 Loss of $0.24
August 9, 2018 4:06 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q2 EPS of ($0.24).
A key highlight of the second quarter is the completion of planting for our 2018 field tests of C3003, said Oliver P. Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. The results of these field tests will allow us to set the direction and priorities for the next steps in the evaluation and development of C3003 as a potentially valuable new... More
